NeOnc Technologies received Investigational New Drug (IND) approval from Abu Dhabi for NEO212, an oral drug targeting aggressive brain tumors like glioblastoma. This marks the first international regulatory clearance for NEO212, complementing ongoing U.S. FDA discussions and expanding NeOnc's global clinical development options. The approval supports NeOnc's strategy to address brain cancer challenges by improving drug delivery past the blood-brain barrier. Investors are also watching upcoming data from NEO100 and insider buying by CEO Amir Heshmatpour, signaling confidence in the company's growth and innovation in neuro-oncology.
Zealthy has broadened its insurance coordination program to assist patients prescribed GLP-1 weight-loss medications like Wegovy and Ozempic. The expanded service helps with insurance verification, prior authorizations, and coverage communications, a...
Markets are rallying as investors anticipate potential Federal Reserve rate cuts later in 2026, boosting equities, cryptocurrencies, and other risk assets. QuantRate has introduced a free AI-powered quant trading bot to help retail investors access a...
China's 15th Five-Year Plan (2026-2030) focuses on innovation, resilience, and quality growth, aiming to lead in sectors like quantum computing and 5G. Former EU economist Rudy Aernoudt highlights China's clear, unified long-term planning approach as...
DelphX Capital Markets finalized a senior secured lending agreement with a major digital asset lender to fund its BTC Structured Income Program, aiming to optimize capital use and scale issuance. The company is also in talks with a large U.S. insurer...
Ironman International Ltd. announced a working capital adjustment payment of $9.83 million to former shareholders of acquired companies, payable in equal installments over five years with 8% annual interest. The company also amended the terms of a $1...
